Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin-Reference-Cited by-同舟云学术

Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin

Published:2016-07-20 Issue:348 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Liu Yanqing¹,Zheng Xiaoli¹,Yu Qinqin¹,Wang Hua²,Tan Fuqing³,Zhu Qianying¹,Yuan Lingmin¹,Jiang Huidi¹,Yu Lushan¹,Zeng Su¹

Affiliation:

1. Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

2. Department of Urology, Cancer Hospital of Zhejiang Province, Hangzhou 310022, China.

3. Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.

Abstract

The expression of drug transporter OCT2 is suppressed in renal cell carcinoma, and targeting this pathway sensitizes the tumor to oxaliplatin.

Funder

National Natural Science Foundation of China

International Science and Technology Cooperation Program of China

Fundamental Research Funds for the Central Universities of China Ministry of Education

Program for Zhejiang Leading Team of S&T Innovation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference51 articles.

1. EAU Guidelines on Renal Cell Carcinoma: The 2010 Update

2. Renal cell carcinoma

3. Oxaliplatin, 5-Fluorouracil, and Folinic Acid (Folfox) in Patients With Metastatic Renal Cell Carcinoma

4. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma

5. The resurgence of platinum-based cancer chemotherapy

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An anti-neoplastic tale of metformin through its transport;Life Sciences;2024-09

2. Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials;Materials Today Bio;2024-08

3. DNA Methylation as Drug Sensitivity Marker in RCC: A Systematic Review;Epigenomes;2024-07-15

4. Nanomaterial-related hemoglobin-based oxygen carriers, with emphasis on liposome and nano-capsules, for biomedical applications: current status and future perspectives;Journal of Nanobiotechnology;2024-06-16

5. Regulation of renal organic cation transporters;FEBS Letters;2024-06-03